Effect of pinitol treatment on insulin action in subjects with insulin resistance

Ajuah Davis, Mark Christiansen, Jeffrey F. Horowitz, Samuel Klein, Marc K. Hellerstein, Richard E. Ostlund

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

OBJECTIVE - Endogenous low-molecular-weight glycans containing pinitol (3-O-methyl-D-chiro-inositol) and D-chiro-inositol are thought to mediate certain actions of insulin. We tested the hypothesis that oral administration of soybean-derived pinitol would improve insulin sensitivity in obese subjects (BMI = 36.6 kg/m2) with diet-treated type 2 diabetes or glucose intolerance (HbA(1c) = 6.8%). RESEARCH DESIGN AND METHODS - There were 22 subjects randomized to receive either pinitol 20 mg · kg-1 · day-1 (n = 12) or placebo (n = 10) in a 28-day double blinded trial. RESULTS - No toxicity due to the pinitol was observed during the study. The sensitivity of glucose and lipid metabolism to insulin were assessed by measurement of whole-body glucose, palmitate, and glycerol kinetics during basal conditions and a hyperinsulinemic-euglycemic clamp. Metabolic measurements were made at baseline and again at the end of the study final plasma levels of pinitol were 48-fold (1.06 ± 0.15 vs. 0.02 ± 0.01 μmol/l, P < 0.0001) and D-chiro- inositol levels 14-fold (0.56 ± 0.08 vs. 0.04 ± 0.02 μmol/l, P < 0.0001) greater in the pinitol group compared with placebo. CONCLUSIONS - Four weeks of pinitol treatment did not alter baseline glucose production, insulin- mediated glucose disposal, or rates of appearance of free fatty acids and glycerol in plasma. We conclude that plasma levels of both pinitol and D- chiro-inositol are very responsive to pinitol ingestion, but insulin sensitivity does not increase after pinitol treatment in individuals with obesity and mild type 2 diabetes.

Original languageEnglish (US)
Pages (from-to)1000-1005
Number of pages6
JournalDiabetes Care
Volume23
Issue number7
StatePublished - 2000

Fingerprint

Insulin Resistance
Insulin
Inositol
Therapeutics
Glucose
Glycerol
Type 2 Diabetes Mellitus
pinitol
Placebos
Glucose Clamp Technique
Glucose Intolerance
Palmitates
Lipid Metabolism
Soybeans
Nonesterified Fatty Acids
Polysaccharides
Oral Administration
Research Design
Obesity
Eating

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Davis, A., Christiansen, M., Horowitz, J. F., Klein, S., Hellerstein, M. K., & Ostlund, R. E. (2000). Effect of pinitol treatment on insulin action in subjects with insulin resistance. Diabetes Care, 23(7), 1000-1005.

Effect of pinitol treatment on insulin action in subjects with insulin resistance. / Davis, Ajuah; Christiansen, Mark; Horowitz, Jeffrey F.; Klein, Samuel; Hellerstein, Marc K.; Ostlund, Richard E.

In: Diabetes Care, Vol. 23, No. 7, 2000, p. 1000-1005.

Research output: Contribution to journalArticle

Davis, A, Christiansen, M, Horowitz, JF, Klein, S, Hellerstein, MK & Ostlund, RE 2000, 'Effect of pinitol treatment on insulin action in subjects with insulin resistance', Diabetes Care, vol. 23, no. 7, pp. 1000-1005.
Davis A, Christiansen M, Horowitz JF, Klein S, Hellerstein MK, Ostlund RE. Effect of pinitol treatment on insulin action in subjects with insulin resistance. Diabetes Care. 2000;23(7):1000-1005.
Davis, Ajuah ; Christiansen, Mark ; Horowitz, Jeffrey F. ; Klein, Samuel ; Hellerstein, Marc K. ; Ostlund, Richard E. / Effect of pinitol treatment on insulin action in subjects with insulin resistance. In: Diabetes Care. 2000 ; Vol. 23, No. 7. pp. 1000-1005.
@article{57ece1ab945341acb88042a4db651237,
title = "Effect of pinitol treatment on insulin action in subjects with insulin resistance",
abstract = "OBJECTIVE - Endogenous low-molecular-weight glycans containing pinitol (3-O-methyl-D-chiro-inositol) and D-chiro-inositol are thought to mediate certain actions of insulin. We tested the hypothesis that oral administration of soybean-derived pinitol would improve insulin sensitivity in obese subjects (BMI = 36.6 kg/m2) with diet-treated type 2 diabetes or glucose intolerance (HbA(1c) = 6.8{\%}). RESEARCH DESIGN AND METHODS - There were 22 subjects randomized to receive either pinitol 20 mg · kg-1 · day-1 (n = 12) or placebo (n = 10) in a 28-day double blinded trial. RESULTS - No toxicity due to the pinitol was observed during the study. The sensitivity of glucose and lipid metabolism to insulin were assessed by measurement of whole-body glucose, palmitate, and glycerol kinetics during basal conditions and a hyperinsulinemic-euglycemic clamp. Metabolic measurements were made at baseline and again at the end of the study final plasma levels of pinitol were 48-fold (1.06 ± 0.15 vs. 0.02 ± 0.01 μmol/l, P < 0.0001) and D-chiro- inositol levels 14-fold (0.56 ± 0.08 vs. 0.04 ± 0.02 μmol/l, P < 0.0001) greater in the pinitol group compared with placebo. CONCLUSIONS - Four weeks of pinitol treatment did not alter baseline glucose production, insulin- mediated glucose disposal, or rates of appearance of free fatty acids and glycerol in plasma. We conclude that plasma levels of both pinitol and D- chiro-inositol are very responsive to pinitol ingestion, but insulin sensitivity does not increase after pinitol treatment in individuals with obesity and mild type 2 diabetes.",
author = "Ajuah Davis and Mark Christiansen and Horowitz, {Jeffrey F.} and Samuel Klein and Hellerstein, {Marc K.} and Ostlund, {Richard E.}",
year = "2000",
language = "English (US)",
volume = "23",
pages = "1000--1005",
journal = "Diabetes Care",
issn = "1935-5548",
publisher = "American Diabetes Association Inc.",
number = "7",

}

TY - JOUR

T1 - Effect of pinitol treatment on insulin action in subjects with insulin resistance

AU - Davis, Ajuah

AU - Christiansen, Mark

AU - Horowitz, Jeffrey F.

AU - Klein, Samuel

AU - Hellerstein, Marc K.

AU - Ostlund, Richard E.

PY - 2000

Y1 - 2000

N2 - OBJECTIVE - Endogenous low-molecular-weight glycans containing pinitol (3-O-methyl-D-chiro-inositol) and D-chiro-inositol are thought to mediate certain actions of insulin. We tested the hypothesis that oral administration of soybean-derived pinitol would improve insulin sensitivity in obese subjects (BMI = 36.6 kg/m2) with diet-treated type 2 diabetes or glucose intolerance (HbA(1c) = 6.8%). RESEARCH DESIGN AND METHODS - There were 22 subjects randomized to receive either pinitol 20 mg · kg-1 · day-1 (n = 12) or placebo (n = 10) in a 28-day double blinded trial. RESULTS - No toxicity due to the pinitol was observed during the study. The sensitivity of glucose and lipid metabolism to insulin were assessed by measurement of whole-body glucose, palmitate, and glycerol kinetics during basal conditions and a hyperinsulinemic-euglycemic clamp. Metabolic measurements were made at baseline and again at the end of the study final plasma levels of pinitol were 48-fold (1.06 ± 0.15 vs. 0.02 ± 0.01 μmol/l, P < 0.0001) and D-chiro- inositol levels 14-fold (0.56 ± 0.08 vs. 0.04 ± 0.02 μmol/l, P < 0.0001) greater in the pinitol group compared with placebo. CONCLUSIONS - Four weeks of pinitol treatment did not alter baseline glucose production, insulin- mediated glucose disposal, or rates of appearance of free fatty acids and glycerol in plasma. We conclude that plasma levels of both pinitol and D- chiro-inositol are very responsive to pinitol ingestion, but insulin sensitivity does not increase after pinitol treatment in individuals with obesity and mild type 2 diabetes.

AB - OBJECTIVE - Endogenous low-molecular-weight glycans containing pinitol (3-O-methyl-D-chiro-inositol) and D-chiro-inositol are thought to mediate certain actions of insulin. We tested the hypothesis that oral administration of soybean-derived pinitol would improve insulin sensitivity in obese subjects (BMI = 36.6 kg/m2) with diet-treated type 2 diabetes or glucose intolerance (HbA(1c) = 6.8%). RESEARCH DESIGN AND METHODS - There were 22 subjects randomized to receive either pinitol 20 mg · kg-1 · day-1 (n = 12) or placebo (n = 10) in a 28-day double blinded trial. RESULTS - No toxicity due to the pinitol was observed during the study. The sensitivity of glucose and lipid metabolism to insulin were assessed by measurement of whole-body glucose, palmitate, and glycerol kinetics during basal conditions and a hyperinsulinemic-euglycemic clamp. Metabolic measurements were made at baseline and again at the end of the study final plasma levels of pinitol were 48-fold (1.06 ± 0.15 vs. 0.02 ± 0.01 μmol/l, P < 0.0001) and D-chiro- inositol levels 14-fold (0.56 ± 0.08 vs. 0.04 ± 0.02 μmol/l, P < 0.0001) greater in the pinitol group compared with placebo. CONCLUSIONS - Four weeks of pinitol treatment did not alter baseline glucose production, insulin- mediated glucose disposal, or rates of appearance of free fatty acids and glycerol in plasma. We conclude that plasma levels of both pinitol and D- chiro-inositol are very responsive to pinitol ingestion, but insulin sensitivity does not increase after pinitol treatment in individuals with obesity and mild type 2 diabetes.

UR - http://www.scopus.com/inward/record.url?scp=0033939877&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033939877&partnerID=8YFLogxK

M3 - Article

C2 - 10895854

AN - SCOPUS:0033939877

VL - 23

SP - 1000

EP - 1005

JO - Diabetes Care

JF - Diabetes Care

SN - 1935-5548

IS - 7

ER -